Home / Transcripts / AVITA Medical, Inc. (RCEL) · February 12, 2026

AVITA Medical, Inc. (RCEL) Earnings Call Transcript

February 12, 2026

NASDAQ US Health Care Biotechnology earnings 31 min

Earnings Call Speaker Segments

Ben Atkins executive
#1

Thanks, operator. I'd like to welcome everyone to the earnings call for AVITA Medical covering both the fourth quarter and the full year 2025. With me today are Cary Vance, who is serving as Interim Chief Executive Officer, and David O'Toole, our Chief Financial Officer. You can find today's earnings release along with the presentation on our website, www.avitamedical.com, in the Investor Relations section. Before diving in, I want to note that forward-looking statements, as defined under the Private Securities Litigation Reform Act of 1995, are part of this call. Such statements should not be viewed as promises or guarantees, and they carry both known and unknown risks and uncertainties that might lead actual results to differ materially from any expectations stated or suggested by those forward-looking statements. For full details on the risk factors, please look at our latest filings with the SEC. All forward-looking statements made on this call reflect management's expectations as of today. At this point, I'll hand things over to Cary.

Cary Vance executive
#2

Hello to our listeners in the United States this afternoon, and to those of you in Australia, good morning. Thank you for joining us. Ahead of getting into the numbers, I want to resume from the point where our last call concluded; when Q3 ended, I closed by identifying 3 priorities: chasing disciplined execution, honing our commercial emphasis and getting AVITA ready for growth in 2026. The fourth quarter was entirely focused on making good on those promises. As you can see on the slide in front of you, we closed out the year with a more disciplined operating model, stronger visibility into cash usage, and a solid understanding of how customers adopt and use our products. We refined our commercial emphasis on utilization within our core burn and trauma centers, and just as important, we removed the friction points, reimbursement ambiguity, and tight balance sheet limitations that had held back execution throughout all of 2025. Individually, these aren't the kinds of results that grab headlines, but collectively, they count. They leave the business easier to understand, easier to predict, and easier to repeat. During today's discussion of the quarter, you'll see those execution priorities showing up in the numbers, in how we run our operating cadence, and in the position we built as we headed toward 2026. Let me turn briefly to the results. Revenue for the fourth quarter was $17.6 million, and for the full year it came to roughly $71.6 million. That works out to about 11% growth compared with 2024, and it landed right where our updated revenue guidance said it would. From where I sit, the fourth quarter was defined less by acceleration and more by control. What the numbers show is a business running with more predictability and more discipline. David will take you through the details shortly. One of the biggest things we focused on during 2025 was clearing up the reimbursement uncertainty surrounding RECELL. Right now, six out of the seven Medicare administrative contractors have posted rates for RECELL procedures. That lifts a major hurdle that held back usage all year and is starting to bring clinicians' confidence back. Like we mentioned last quarter, when reimbursement is dependable — both for what we sell and for the people administering it — our solid clinical and real-world health economic evidence can finally turn into everyday, standard use of RECELL. Now that this is settled, we're already noticing the first hints that utilization is starting to get back to normal as accounts become active again. At the end of the day, what really fuels expansion here isn't so much signing up additional hospitals—it's getting clinicians to adopt, use and keep coming back to RECELL, Cohealyx and PermeaDerm. Around 200 burn and trauma centers generate approximately 90% of our revenue right now. So we've reoriented our sales incentives, our forecasting assumptions and what our field teams focus on toward driving earlier adoption and repeat usage inside those core accounts. On top of that, we keep moving away from large bulk orders and toward more natural month-to-month usage. Why does utilization matter? Because it brings predictability—for clinicians, for hospitals and for us as a company. Going forward, utilization will play a bigger and bigger role in how we judge our own execution internally. Right now, what matters most is getting our operating rhythm right and excelling at the basics, so that improvement can build and multiply as time goes on. The scope of our platform is what makes that steadiness possible. Everything we do centers on one connected platform — RECELL, Cohealyx, and PermeaDerm — employed again and again by the same doctors across many patient episodes. RECELL is still the core of what we do, backed by a large body of clinical evidence showing quicker healing, better results, and fewer days in the hospital. Enrollment is complete for the Cohealyx-1 post-market study, and the PermeaDerm-1 study is close to being fully enrolled; both are meant to produce useful real-world clinical and economic proof of how surgeons actually apply these products in wound care, with data anticipated in the latter part of 2026. Investigators shared early results and case experiences from these studies at last month's 2026 Boswick Burn and Wound Symposium. Also worth mentioning: two podium presentations covered cases where a single patient received all three of our technologies together — RECELL, Cohealyx, and PermeaDerm. That demonstrates how our transition from a company defined solely by RECELL into a multiproduct acute wound care platform is now appearing in real clinical settings, together with opportunities for higher revenue per patient. Outside the United States, we are pursuing a disciplined, distributor-led approach as we move into selected markets where the clinical need is clear and the required regulatory and operational foundations are in place. Following CE Mark approval for RECELL GO last October, we have supported initial clinical adoption in several European markets, concentrating on establishing familiarity and operational readiness. After the terrible nightclub fire that happened in Crans-Montana, Switzerland, our people and our distribution partners were able to move quickly when surgeons reached out, since that foundation had been put in place beforehand. In moments such as these, what we must do is remain quick to act and reliable as we support patient care under extraordinarily difficult circumstances. Together with the burn care community, we will continue our joint efforts to ensure RECELL can be obtained at any time and in any place it is needed. David will walk you through how our commitment to execution discipline is reflected in our financial results, particularly in our cost structure, our cash usage, and our balance sheet. Back in January, we went through a refinancing of our debt, putting in place a fresh credit facility with Perceptive Advisors, LLC. The main goal there wasn't really to bring in additional capital — it was to get rid of the distraction that restrictive covenants were creating, so the organization could stay focused on execution. Turning to 2026, we're expecting revenue for the full year to land somewhere between $80 million and $85 million. That translates to somewhere in the neighborhood of 12% to 19% growth compared with 2025. The guidance rests on a few assumptions: RECELL utilization getting back to normal levels, wider use of the portfolio across core accounts, contributions coming from Cohealyx and PermeaDerm, and a more stable operating environment. What drives this growth is execution — consistent delivery quarter after quarter — rather than one-off events or aggressive assumptions. With that, I'll hand the call to David so he can take you through the financials in greater depth.

David OToole executive
#3

Thanks, Cary, and hello everyone this afternoon. Like Cary said, Q4 wrapped up a year in which AVITA stabilized and moved toward a phase centered more on execution. I want to take you through how that discipline shows up in the figures, especially when it comes to costs, cash burn and the balance sheet. Starting with the full year picture for 2025. Revenue came in at about $71.6 million, which works out to 11% growth versus 2024. That gave the company yet another consecutive year of top-line expansion and shows a business still growing even with the reimbursement-related pressures. Gross margin for the full year landed at 82.1%, versus 85.8% in 2024. The decline comes from certain inventory reserves plus the effect of product mix and a bigger contribution from Cohealyx and PermeaDerm. As we've said before, although mix drags on the reported margin percentage, these products add incremental gross profit without a matching rise in operating expenses, which supports operating leverage down the road. Pairing year-over-year revenue growth with gross margins above 80% gives us a strong base as we move ahead. Now to Q4. Total revenue reached $17.6 million, against $18.4 million in the same period a year earlier. That matched our revised revenue expectations and demonstrated stabilization in the business. Gross margin for Q4 was 81.2%, versus 87.6% in last year's comparable period, due to inventory reserves and product mix. Onto operating costs. Q4 total operating expenses came to $24.7 million, a 5% decline year-over-year. That drop was mostly from lower sales and marketing spending, reflecting fewer people, reduced compensation and lower commissions after the commercial transformation earlier in the year. G&A was basically unchanged, while R&D rose modestly on planned investment in our PermeaDerm and Cohealyx post-market studies. Q4 carried $1.2 million in onetime severance costs, which won't repeat. Strip those out and Q4 operating expenses fell 10% year-over-year. Across the full year, even counting the nonrecurring severance costs, operating expenses came down by $10.4 million, or 9%, which reflects a much leaner operating structure going forward. Now to cash. The main point is better control and visibility over how we use cash. Q4 was the third straight quarter of improvement in net cash used, falling from $10.1 million in Q2 to $6.2 million in Q3 and $5.1 million in Q4. Looking ahead to Q1 of 2026, cash use will rise because of the timing of annual compensation and payroll-related items, which we expect and have planned for in our operating model. We finished the quarter with $18.2 million in cash and marketable securities. In January, we refinanced our debt via a new credit facility with Perceptive Advisors, LLC. The levels and flexibility in that facility line up much better with the operating trajectory we're on now. Under the new agreement, the revenue and cash covenants give us substantially more headroom. To give you a sense of the scale, the first trailing 12-month covenant sits at $68.5 million, which works out to just $15.4 million of revenue in Q1 before the revenue covenant would be tripped; when you look at the whole of 2026, the $73 million trailing 12-month threshold sits well below the revenue guidance we've given for 2026. Beyond that, the minimum cash requirement now stands at $5 million rather than $10 million, which cuts covenant risk considerably and underscores that this facility was built to back execution, not hold it back. There's no amortization — it's interest-only — and it carries optional incremental capital should we need it, contingent on hitting a particular revenue milestone. Taking a step back, the point of this refinancing was to make the balance sheet simpler, cut down on friction and take away distraction. Financially speaking, our 2026 priorities are clear: keep operating costs under disciplined control, back revenue growth through a cost structure that is stable and scalable, and keep delivering cash efficiency as revenue climbs. With that framework in place, along with a stronger capital structure and clear visibility into 2026 growth, we think AVITA is in a better spot to execute consistently and progress toward financial sustainability. I'll now hand the call back to Cary.

Cary Vance executive
#4

Appreciate that, David. To wrap up, the steps we've implemented across the last several months have put AVITA in a position for a stronger and more consistent 2026. Reimbursement clarity has been restored, our commercial focus has been simplified, operational friction has been removed, financial discipline has been strengthened, and the clinical evidence supporting our multiproduct platform has been advanced. Those steps establish the execution milestones we'll report against all year long. As we progress through 2026, our focus is simple. Do what we said we would do, report it clearly and let execution speak for itself; with that, let's open for questions.

Ryan Zimmerman analyst
#5

Regarding the outlook, David, given those fresh revenue covenants, how should we view the growth rate across the year? Would 15.4% serve as a solid starting point for Q1? Or is the intent to signal that this figure sits far beneath what you're capable of achieving, meaning no covenant danger exists there? That would be helpful to hear. Then I have another question.

David OToole executive
#6

Right; and I'm certain Cary might want to add a few points too. But Brian, that $15.4 million ought not to be viewed as any sort of guidance whatsoever. Our aim is exactly what you mentioned — to show there's substantial room relative to that covenant figure of $15.4 million. During the fourth quarter, we posted $17.6 million. A drop that large in Q1 isn't something we'd anticipate. Our guidance stands at $80 million to $85 million; and simply multiplying that across 4 quarters wouldn't bring you anywhere near $15.4 million. So as you're aware, quarterly guidance isn't something we provide. The purpose of citing that $15.4 million was simply to communicate that the fresh debt was arranged so covenant risk got eliminated, and that's precisely what happened.

Ryan Zimmerman analyst
#7

Please go ahead, Cary — my apologies.

Cary Vance executive
#8

Right, Ryan. So yeah, I'd simply add to what's been said there. Q4 is what I'd call our starting block. What we aim to accomplish during Q4 is, in a sense, to smooth everything out and bring a sense of normalcy to how orders come in and how well we can predict them. That leaves us feeling confident not just about how Q4 turned out, but also about our grip on the business — enough that we could, I believe, get a read on Q1. And as far as we can tell, we still have a handle on Q1. So my sense is that between Q4 and Q1, and then from Q1 across the remainder of the year, what you ought to witness is growth that builds steadily, an acceleration that happens step by step. And I think our grasp of this business is solid, with more updates to come on that front.

Ryan Zimmerman analyst
#9

Thanks for that, Cary. We could take a moment to discuss the reimbursement trends that shaped 2025. It seems like a lot of what held 2025 back involving the MACs is now resolved. But could you provide additional detail about how payment has been restored across 6 of the 7 MACs? What can you now state with confidence? And what is delaying the seventh MAC? Should we be worried about anything, or is this purely an administrative matter? Perhaps you could also walk us through what has happened over the past quarter, say, and into the first quarter?

Cary Vance executive
#10

Absolutely. To start, we are deeply involved with all 7. I'd group these into categories: we received assurances months back that they would publish, and subsequently they did publish. After publication, it becomes a question of hospital by hospital, physician by physician, them learning about it and then applying it in practice for reimbursement and restoring a predictability that will serve us moving forward. That has happened as each MAC gradually joined in. Regarding the seventh one, we remain deeply involved with them. All I can say is there is nothing to worry about; we are simply working with them through a process of theirs, and we are optimistic and anticipate that they will publish too.

Josh Jennings analyst
#11

Congrats on everything you've accomplished with the refinancing, and it's wonderful to see payment rates locked in for the 60 7 MACs. First thing I'd like to ask: could you walk us through one example of a core customer experience in which Cohealyx and PermeaDerm have successfully cleared the back process? Also, what signals are you noticing, if any, that give you belief there can eventually be solid attachment rates for Cohealyx and PermeaDerm within RECELL cases?

Cary Vance executive
#12

Sure. So, thanks, Josh. What happens, I'd say, is that in certain of these accounts we've got a champion — someone backing PermeaDerm and/or Cohealyx — and alongside that person we engage clinically and economically to build their understanding of the value; after that it enters the back, and that champion is the one who keeps it moving forward. The thinking there is that when it emerges from the back, that very same champion begins driving it into the department and into their practice. That pattern has shown up at a handful of the MACs that have come — sorry, at a handful of the MACs where those products have exited; and on our end it's worked well, generating some uptake once things clear the back.

Josh Jennings analyst
#13

Great. Is there, like, a marquee account in which Cohealyx and PermeaDerm have cleared that back process, and you're seeing solid attachment rates on cases involving RECELL?

Cary Vance executive
#14

Honestly, at this moment I don't think I could single one out. That said, while we were attending the Boswick Burn Conference — which I mentioned during my remarks — a few presentations took place from physicians who had utilized all 3 products: RECELL, Cohealyx and PermeaDerm. And once again, I'd characterize it as very early when it comes to anybody using all 3 of those. Still, I believe we'll be in a position to share more down the road, as these products emerge from the back and as they start being employed alongside one another.

Josh Jennings analyst
#15

Got it. And you've still got the Cohealyx-1 and PermeaDerm-1 study data that can support that utilization path? And in the end, I guess, do you expect Cohealyx and PermeaDerm uptake to also push up demand for RECELL? I've just been wondering about RECELL pulling Cohealyx and PermeaDerm through, but looking ahead, might Cohealyx and PermeaDerm reach additional accounts or simply lift utilization within that base of 200 trauma/burn centers?

Cary Vance executive
#16

Yeah. That's a fair question. RECELL, I'd say, is the established brand. It's the offering that's been on the market the longest. Still, in the end, we do have relationships at these accounts. We have physicians using RECELL who, I believe, are at minimum intrigued by and willing to talk about Cohealyx and PermeaDerm, thanks to the relationship we've built and their fondness for RECELL. That said, you're correct — I think those physicians who might not be using RECELL, or even institutions that might not use RECELL, if Cohealyx appeals to them or we ultimately achieve real progress there, then naturally it lets you form a connection and build a relationship there and engage in dialogue about treatment and care that might open the door to a RECELL conversation too.

Josh Jennings analyst
#17

Great. And perhaps as a final point, I believe I already know what you'll say here, but I'd like to tick that box given some of the instability surrounding MACs and the payment rate for RECELL — particularly as you begin to observe adoption and utilization of Cohealyx and PermeaDerm across 2026. Could you walk us through the reimbursement pathway once more? I think it's a straightforward path with no obstacles ahead, but again, just to tick that box. Laying it out would be terrific.

Cary Vance executive
#18

Yeah. Again, I believe your assessment is right. We've spent the past year managing those physician payments via the MAC, yet beyond continuing to resolve these matters over the coming months, we anticipate no further interruptions to that process.

Ian Arnt analyst
#19

Could you guys unpack what's mainly fueling the growth that underpins your 2026 guidance? To put a finer point on it, how much of that is tied to the rebound in those RECELL lines, and how much comes from the Cohealyx and PermeaDerm launches?

Cary Vance executive
#20

Could you say that again? The audio is a bit low; I'm having trouble making out the question.

Ian Arnt analyst
#21

Yeah, my apologies for that. I wanted to ask whether you could sort of unpack what's mainly fueling the growth behind your 2026 guidance — more specifically, what portion rests on a rebound in base RECELL volumes, and what portion comes from fresh contributions tied to the Cohealyx and PermeaDerm launches?

Cary Vance executive
#22

Yeah. Thanks; the mix will vary. What I'd say is that growth should come across all 3 product lines, and the bulk of it should come from higher utilization inside accounts we already have, whether through more physicians or more kinds of procedures. So that's the utilization path we're seeing, and that's the plan we've put in place. So all 3 product lines ought to expand, and mostly that expansion should happen inside existing institutions where relationships are already established as we move through the year.

Ian Arnt analyst
#23

All right. That helps a lot; and if it's all right, I have a fast follow-up; during Q3, you mentioned that about one-third of your target accounts were sitting in the VAC review for Cohealyx. Could you give us an update on how many of those reviews have converted and on the accounts that are actively ordering? And are there any particular bottlenecks you're noticing in that process?

Cary Vance executive
#24

Any — sorry, am I seeing — at the moment, we have, sorry, at the moment, what number do we have in Cohealyx VAC? Was that what you asked?

Ian Arnt analyst
#25

Sure. Building on what was mentioned regarding the third quarter, could you provide an update about how many of those reviews have converted into active ordering accounts? Do any bottlenecks exist within that process? Or might that push back the 2026 ramp?

Cary Vance executive
#26

Sure. Rather than simply providing a figure, I'd say they keep emerging from VAC, Cohealyx VAC, at what I would call a steady pace, and our expectation would be that this happens across the coming, let's say, 6 to 9 months. So as they exit the VAC, they begin placing orders for product. For us, then, this becomes an ongoing week-by-week, month-by-month, quarter-by-quarter effort of anticipating and understanding that they will exit the VAC and, once they do, getting them to order sooner, larger, faster, and to have a very positive experience with it, obviously, as well and to develop more than just that one champion in the account so that it can broaden and deepen; but what we aren't — what we aren't observing in the VACs is bottlenecks aside from administrative bottlenecks. They simply go through their process, and there is no set time. It depends on the account. And we give them all the information, whether clinical or economic, to make the argument that it should successfully go through the VAC. So we haven't really seen denials through the VAC, but it is a process that takes some time, and we've seen that.

Cary Vance executive
#27

Appreciate it, operator. And thanks as well to all the rest of you who are here with us today. I'm eager to share updates with you on how things develop over the coming quarters. So, my thanks. Enjoy the remainder of your day. Thanks.

Operator operator
#28

We appreciate everyone joining us for this call today. That brings the program to a close. You're welcome to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete AVITA Medical, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to AVITA Medical, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.